Partner Headlines - MDVN

  1. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  2. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  3. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  4. Benzinga's Top Upgrades

    Benzinga
  5. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  6. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  7. Morning Market Movers

    Benzinga
  8. Stocks To Watch For April 1, 2014

    Benzinga
  9. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  10. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  11. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  12. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  13. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  16. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  17. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  18. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  19. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  20. Stocks Hitting 52-Week Highs

    Benzinga
  21. Benzinga's Top #PreMarket Gainers

    Benzinga
  22. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  23. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  24. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  25. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  26. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  27. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  28. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  29. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  30. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  31. Benzinga's Top Initiations

    Benzinga
  32. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  33. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  34. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  35. Medivation Effects 2-for-1 Stock Split

    Benzinga
  36. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  37. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  38. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  39. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  40. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  41. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  42. Stocks Hitting 52-Week Highs

    Benzinga
  43. Health Care Sector Wrap

    FoxBusiness
  44. Four Winning Trades Based on Analyst Calls

    Benzinga
  45. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  46. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  47. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  48. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  49. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  50. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  51. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  52. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  53. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  54. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  55. Will Johnson & Johnson Cure Cancer?

    Benzinga
  56. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  57. Notable Put Options Activity in Medivation

    Benzinga
  58. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  59. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  60. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  61. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  62. Jefferies Raises PT on Medivation to $95

    Benzinga
  63. Wedbush Raises PT on Medivation to $81

    Benzinga
  64. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  65. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  66. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  67. Alzheimer's drug test halted

    IBD
  68. Best Biotech Stocks of 2011

    Benzinga
  69. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  70. Notable Put Options Activity in Medivation

    Benzinga
  71. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center